TCM
BOLD

Tekla Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Tekla Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-52,574
Closed -$1.99M – 208
2019
Q2 		$1.99M Hold
52,574
– – 0.08% 134
2019
Q1 		$2.05M Hold
52,574
– – 0.08% 130
2018
Q4 		$1.12M Buy
52,574
+13,834
+36% +$357K 0.05% 160
2018
Q3 		$1.53M Buy
+38,740
New +$1.44M 0.06% 168

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Tekla Capital Management's BOLD Position: Q3 2019 in Review

Tekla Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2019, closing a stake of 52,574 shares — an estimated $1.99M sold.

Tekla Capital Management first reported a position in BOLD in Q3 2018 and held it in 4 quarters. The position peaked at $2.05M in Q1 2019. 149 funds tracked by Wall St. Rank hold BOLD as of Q3 2019.

  • Tekla Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Tekla Capital Management sold 52,574 Audentes Therapeutics, Inc shares in Q3 2019, an estimated $1.99M.
  • Tekla Capital Management first reported a position in Audentes Therapeutics, Inc in Q3 2018 and held it in 4 quarters.
  • Tekla Capital Management's Audentes Therapeutics, Inc position peaked at $2.05M in Q1 2019.
  • 149 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2019.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.